July 24, 2012 — The importance of utilizing computed tomography (CT) in pre-planning for transcatheter aortic valve implementation (TAVI) and the benefits from viewing CT images via the Philips IntelliSpace Portal was highlighted at the 7th Annual Society of Cardiovascular Computed Tomography (SCCT) Scientific Meeting, July 19-22 in Baltimore, Md.

July 24, 2012 — GE Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its new cardiac imaging platform, the Discovery CT750 HD FREEdom Edition.

Discovery CT750 HD FREEdom Edition

July 24, 2012 — Mevion Medical Systems announced today that it has delivered the superconducting synchrocyclotron for the Mevion S250 Proton Therapy System currently under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J., the flagship cancer hospital of The Cancer Institute of New Jersey and the principle teaching hospital of UMDNJ-Robert Wood Johnson Medical School.

July 24, 2012 — Navidea Biopharmaceuticals Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that clinical data from a head-to head study comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PiB (PiB), was presented at the Alzheimer's Association International Conference (AAIC) in Vancouver, Canada by Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia.

July 24, 2012 — Carestream launched its new Vita XE CR imaging system, which is now available for order worldwide. The tabletop computed radiography (CR) system produces diagnostic quality images at a speed of 60-plus plates per hour and is an ideal fit for smaller hospitals, imaging centers, clinics and private practices.

July 24, 2012 — M*Modal, a provider of clinical documentation and speech understanding solutions, announced United Hospital System has selected the M*Modal Fluency family of cloud-based solutions to deliver advanced clinical documentation to its health system and physicians.

July 23, 2012 — GE Healthcare announced the final results from a Phase III study of the investigational PET (positron emission tomography) amyloid imaging agent, F-18 flutemetamol, in terminally ill patients who had agreed to undergo postmortem brain autopsy. The data showed strong concordance (sensitivity and specificity) between flutemetamol PET images and beta amyloid brain histopathology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now